|
Change of Director's Interest Notice - Rennie
|
7 June 2023 at 8:50am
|
|
Change of Director's Interest Notice - Uvarov
|
25 May 2023 at 4:00pm
|
|
Change of Director's Interest Notice - Rennie
|
25 May 2023 at 3:35pm
|
|
Change of Director's Interest Notice - Uvarov
|
19 May 2023 at 7:00pm
|
|
Change of Director's Interest Notice - Rennie
|
18 May 2023 at 2:25pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 8:35am
|
|
Positive treatment effect in MS animal study
|
14 March 2023 at 11:35am
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 8:20am
|
|
Notification of cessation of securities - NSB
|
6 February 2023 at 3:25pm
|
|
Investor Update Presentation
|
3 February 2023 at 2:05pm
|
|
Investor Update Webinar
|
2 February 2023 at 6:00pm
|
|
R&D Tax Incentive Refund Received
|
2 February 2023 at 10:50am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 11:30am
|
|
Patent Application - Updated Announcement
|
15 December 2022 at 1:10pm
|
|
NSB files new patent
|
5 December 2022 at 8:50am
|
|
Results of Meeting
|
24 November 2022 at 6:15pm
|
|
Chair's address to shareholders & AGM presentation
|
24 November 2022 at 4:10pm
|
|
Appointment of Interim CEO
|
23 November 2022 at 8:45am
|
|
Executive Management Changes
|
15 November 2022 at 4:55pm
|
|
NSB receives R&D Advance & Overseas Finding
|
14 November 2022 at 5:50pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 8:20am
|
|
Notice of Annual General Meeting
|
21 October 2022 at 8:40am
|
|
Investor Update Presentation
|
20 September 2022 at 12:25pm
|
|
Investor Update Webinar
|
19 September 2022 at 6:10pm
|
|
Final Director's Interest Notice - Liddelow
|
16 September 2022 at 8:40am
|
|
CEO Resignation
|
9 September 2022 at 10:10am
|
|
Investor Update Webinar
|
7 September 2022 at 12:00pm
|
|
HREC decision to not approve Phase I Clinical Trial
|
7 September 2022 at 8:40am
|
|
Corporate Governance Statement
|
30 August 2022 at 8:25am
|
|
Appendix 4G
|
30 August 2022 at 8:25am
|
|
NeuroScientific releases FY2022 Results
|
30 August 2022 at 8:25am
|
|
2022 Annual Report and Appendix 4E
|
30 August 2022 at 8:25am
|
|
R&D Tax Incentive Refund Received
|
17 August 2022 at 8:35am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 July 2022 at 6:35pm
|
|
HREC Submission for Phase I Clinical Trial
|
12 July 2022 at 10:20am
|
|
First Subject Recruited for Early-Phase Clinical Trial
|
30 June 2022 at 10:30am
|
|
Notification of cessation of securities - NSB
|
27 June 2022 at 4:45pm
|
|
Company Presentation - Gold Coast Investment Showcase
|
22 June 2022 at 12:40pm
|
|
Clarification of Results in MS Animal Study
|
22 June 2022 at 8:45am
|
|
Notification regarding unquoted securities - NSB
|
21 June 2022 at 2:15pm
|
|
Issue of Employee Options
|
21 June 2022 at 2:05pm
|
|
Positive results in MS animal study
|
15 June 2022 at 8:45am
|
|
Ethics Approval Granted for Early-Phase Clinical Trial
|
7 June 2022 at 11:40am
|
|
HREC Submission for early-phase Clinical Trial
|
11 May 2022 at 9:50am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 April 2022 at 8:25am
|
|
Positive safety result supports advance to clinical trials
|
13 April 2022 at 10:55am
|
|
NSB Enhances Management Team
|
1 April 2022 at 10:50am
|
|
Company Presentation
|
24 March 2022 at 6:10pm
|
|
NSB presenting at Broker Briefing Investor Webinar
|
23 March 2022 at 8:45am
|
|
New data demonstrates EmtinB activity in autoimmune diseases
|
11 March 2022 at 8:40am
|
NeuroScientific Biopharmaceuticals